{"entity":{"id":"nct06680739","kind":"trial","name":"Single cEll pRofiling PErsistaNce To ImmuNothErapy","aka":["SERPENTINE"],"tldr":"A phase 2 trial of durvalumab and tremelimumab in colorectal cancer, run by Vall d'Hebron Institute of Oncology, now recruiting.","summary":"Single cEll pRofiling PErsistaNce To ImmuNothErapy is a phase 2, interventional study registered as NCT06680739 by Vall d'Hebron Institute of Oncology, with a registry enrolment figure of 60 participants, started 2022-03-01 and due to reach its primary completion in 2032-07-01. Interventions recorded: Durvalumab; Tremelimumab. Conditions listed: Colorectal Cancer; Endometrial Cancer. Primary outcome: Evaluation of Objective Response Rate (ORR). Colorectal eligibility wording from the registry: \", Health Insurance Portability and Accountability Act in the US, European Union \\[EU\\] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations\". Sites: Spain. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06680739","url":"https://clinicaltrials.gov/study/NCT06680739"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["durvalumab","tremelimumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06680739","phase":"2","setting":"Single Cell Characterization of Persistent Cells Upon Treatment With Durvalumab (MEDI4736) With or Without Tremelimumab in MSS and MSI Colorectal and Endometrial Tumors: the SERPENTINE Clinical Trial","sponsor":"Vall d'Hebron Institute of Oncology","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06680739/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}